299 related articles for article (PubMed ID: 28181675)
1. A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer.
van Die MD; Williams SG; Emery J; Bone KM; Taylor JM; Lusk E; Pirotta MV
Prostate; 2017 May; 77(7):765-775. PubMed ID: 28181675
[TBL] [Abstract][Full Text] [Related]
2. Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.
van Die MD; Bone KM; Emery J; Williams SG; Pirotta MV; Paller CJ
BJU Int; 2016 Apr; 117 Suppl 4(Suppl 4):17-34. PubMed ID: 26898239
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.
Pantuck AJ; Pettaway CA; Dreicer R; Corman J; Katz A; Ho A; Aronson W; Clark W; Simmons G; Heber D
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):242-8. PubMed ID: 26169045
[TBL] [Abstract][Full Text] [Related]
5. Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy.
Cipolla BG; Mandron E; Lefort JM; Coadou Y; Della Negra E; Corbel L; Le Scodan R; Azzouzi AR; Mottet N
Cancer Prev Res (Phila); 2015 Aug; 8(8):712-9. PubMed ID: 25968598
[TBL] [Abstract][Full Text] [Related]
6. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer--the U.K. NCRN Pomi-T study.
Thomas R; Williams M; Sharma H; Chaudry A; Bellamy P
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):180-6. PubMed ID: 24614693
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men.
Kjaer TN; Ornstrup MJ; Poulsen MM; Jørgensen JO; Hougaard DM; Cohen AS; Neghabat S; Richelsen B; Pedersen SB
Prostate; 2015 Sep; 75(12):1255-63. PubMed ID: 25939591
[TBL] [Abstract][Full Text] [Related]
9. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
Suzman DL; Zhou XC; Zahurak ML; Lin J; Antonarakis ES
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):49-55. PubMed ID: 25384338
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation.
Choi YH; Han DH; Kim SW; Kim MJ; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY
Prostate; 2019 May; 79(6):614-621. PubMed ID: 30671976
[TBL] [Abstract][Full Text] [Related]
11. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
Marschner N; Rüttinger D; Zugmaier G; Nemere G; Lehmann J; Obrist P; Baeuerle PA; Wolf A; Schmidt M; Abrahamsson PA; Reinhardt C; Heidenreich A
Urol Int; 2010; 85(4):386-95. PubMed ID: 20606402
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D
BJU Int; 2004 Feb; 93(3):275-8. PubMed ID: 14764122
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.
Goluboff ET; Prager D; Rukstalis D; Giantonio B; Madorsky M; Barken I; Weinstein IB; Partin AW; Olsson CA;
J Urol; 2001 Sep; 166(3):882-6. PubMed ID: 11490238
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
Pruthi RS; Johnstone I; Tu IP; Stamey TA
Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
18. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy.
Henning SM; Wang P; Said JW; Huang M; Grogan T; Elashoff D; Carpenter CL; Heber D; Aronson WJ
Prostate; 2015 Apr; 75(5):550-9. PubMed ID: 25545744
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
Tenenholz TC; Shields C; Ramesh VR; Tercilla O; Hagan MP
Urol Oncol; 2007; 25(2):101-9. PubMed ID: 17349523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
